Loncar China BioPharma ETF (CHNA)

18.83
Delayed Data
As of Nov 16
 0.00 / 0.00%
Today’s Change
13.35
Today|||52-Week Range
32.73
-29.63%
Year-to-Date

Investment Objective

The investment seeks to track the performance, before fees and expenses, of the Loncar China BioPharma Index (the index). The Advisor attempts to invest all, or substantially all, of its assets in the component securities and depositary receipts that make up the index. The index seeks to track the performance of a modified equal-weighted portfolio of companies directly involved in the growth of China's pharmaceutical and biotech related industries.

5 Best-Performing ETFs of Last Week
Nov 21 / Zacks.com - Paid Partner Content
 

Performance

1 month+17.47% 3 years-5.65%
3 months+2.17% 5 years--
1 year-39.59% Since inception-5.04%
Data through 12/02/2022

Quote Details

Previous close$18.83
Open day’s range14.94 – 18.83
Net asset value (NAV)17.80 (12/01/2022)
Daily volume107
Average volume (3 months)1,017
Data as of 9:30am ET, 11/16/2022

Peer Comparisonvs. China region ETFs

 CHNACategory
Performance 5-yr return---2.69%
Expense Gross exp ratio0.79%1.09%
Risk 5 year sharpe ratio---0.21
Net assets$4.3M$321.7M
Average market cap$2.4B$35.8B
Average P/E9.49.0
Dividend / Share--0.15%

Competitors

FLTW Franklin FTSE Taiwan ETF
EWT iShares MSCI Taiwan ETF
CNYA iShares MSCI China A ETF

Holdings

Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
-- 3.34%
-- 3.18%
-- 2.97%
BGNE Beigene Ltd2.96%
-- 2.63%
-- 2.58%
-- 2.58%
-- 2.36%
-- 2.35%
-- 2.33%